Why the study?
Does rebamipide prevent small bowel mucosal damage and blood flow reduction in healthy subjects receiving low-dose aspirin?
Does rebamipide prevent small bowel mucosal damage and blood flow reduction in healthy subjects receiving low-dose aspirin?
Rebamipide may prevent small bowel blood flow reduction and mucosal injuries associated with short-term low-dose aspirin use in healthy subjects.
Rebamipide may preserve small bowel blood flow during low-dose aspirin; extends endoscopic protection data to perfusion measures in healthy subjects.
AIM: To investigate the relationship between low-dose aspirin-induced small bowel mucosal damage and blood flow, and the effect of rebamipide. METHODS: Ten healthy volunteers were enrolled in this study. The subjects were divided into two groups: a placebo group given low-dose aspirin plus placebo and a rebamipide group given low-dose aspirin plus rebamipide for a period of 14 d. Capsule endoscopy and contrast-enhanced ultrasonography were performed before and after administration of drugs. Areas under the curves and peak value of time-intensity curve were calculated. RESULTS: Absolute differences in areas under the curves were -1102.5 (95% CI: -1980.3 to -224.7, P = 0.0194) in the placebo group and -152.7 (95% CI: -1604.2 to 641.6, P = 0.8172) in the rebamipide group. Peak values of time intensity curves were -148.0 (95% CI: -269.4 to -26.2, P = 0.0225) in the placebo group and 28.3 (95% CI: -269.0 to 325.6, P = 0.8343) in the rebamipide group. Capsule endoscopy showed mucosal breaks only in the placebo group. CONCLUSION: Short-term administration of low-dose aspirin is associated with small bowel injuries and blood flow.
No takes yet. Share an insight, caveat, or question.
Urara Nishida (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: